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Background: Severe hypertriglyceridemia (HTG) has been linked to defects in LPL, APOC2, APOA5, LMF1 and
GBIHBP1 genes. However, a number of severe HTG cases are probably caused by as yet unidentified mutations.
Very high triglyceride plasma levels (>112 mmol/L at diagnosis) were found in two sisters of a Chilean
consanguineous family, which is strongly suggestive of a recessive highly penetrant mutation. The aim of this study
was to determine the genetic locus responsible for the severe HTG in this family.
Methods: We carried out a genome-wide linkage study with nearly 300,000 biallelic markers (Illumina Human
CytoSNP-12 panel). Using the homozygosity mapping strategy, we searched for chromosome regions with excess
of homozygous genotypes in the affected cases compared to non-affected relatives.
Results: A large homozygous segment was found in the long arm of chromosome 11, with more than 2,500
consecutive homozygous SNP shared by the proband with her affected sister, and containing the APOA5/A4/C3/A1
cluster. Direct sequencing of the APOA5 gene revealed a known homozygous nonsense Q97X mutation
(p.Gln97Ter) found in both affected sisters but not in non-affected relatives nor in a sample of unrelated controls.
Conclusion: The Q97X mutation of the APOA5 gene in homozygous status is responsible for the severe
hypertriglyceridemia in this family. We have shown that homozygosity mapping correctly pinpointed the genomic
region containing the gene responsible for severe hypertriglyceridemia in this consanguineous Chilean family.
Keywords: Hypertriglyceridemia, Genetic, Chylomicronemia, Mutation, Homozygosity mapping, APOA5Background
Hypertriglyceridemia (HTG) is defined as an elevation of
plasma triglycerides (TG) above 1.7 mmol/L, and con-
sidered as severe HTG when it reaches plasma levels
above 5.6 mmol/L [1]. HTG is a common dyslipidemia
in the general population, with a estimated prevalence in
Chile of about 30% [2]. HTG can be divided into primary
and secondary types. Primary HTG is usually caused by a
single genetic defect, while secondary HTG is multifactorial* Correspondence: jsantos@med.puc.cl
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distribution, and reproduction in any mediumand associated with health conditions such as obesity,
diabetes mellitus, insulin resistance or certain drugs [3].
Following the Fredrickson classification, primary HTG
such as hyperlipidemia (HLP) type IV or type V, are
characterized by the cumulative effect of several relatively
common genetic variants in association with adverse en-
vironmental factors [4,5] On the other hand, monogenic
HTG usually manifests clinically as HLP type I. The main
genes known to be responsible for this disorder are LPL
and APOC2 [6]. In recent years, other genes causing se-
vere HTG have been identified such as APOA5,
GPIHBP1 and LMF1 [7-15]. However, it is estimated that
the metabolic and genetic defect underlying primarytral Ltd. This is an Open Access article distributed under the terms of the
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probably other unknown genes involved in the develop-
ment of this disorder [4,16]. On the other hand, Genome
Wide Association Studies (GWAS) have identified gene
variation related to discrete variations in plasma TG levels
in the general population [4]. Thus, common variants in
genes such as GCKR, TRIB1, MLXIPL, GALNT2, APOB,
APOA5, APOE, LPL, APOC2, APOC3, ANGPTL3 and
NCAN (for acronyms see Additional file 1: Table S1) have
shown a significant, although modest effect on plasma
TG [4,5,17-21]. Genotype-phenotype associations from
GWAS and family studies indicated that common and
rare variants in candidate genes are related to mild and
severe HTG [16,20-22]. On the other hand, homozygosity
mapping is a straightforward approach based on linkage
analysis suitable for the study of autosomal recessive dis-
eases in consanguineous families [23]. This strategy has
been successfully employed in the identification of the
genetic cause of diseases such as congenital generalized
lipodystrophy, Allstrom syndrome or complete achroma-
topsia, among others [24-26]. Thus, this approach may be
used for the identification of causative genes of severe
HTG in consanguineous families with multiple family
members affected.
The aim of the present study is to identify the gene
and mutation responsible for the severe HTG (plasma
TG >112 mmol/L) found in two sisters of a consanguin-
eous Chilean family. For this purpose, we performed a
genome scan using nearly 300,000 biallelic markers (Single
Nucleotide Polymorphism: SNP). Through extensive
search of regions showing consecutive homozygous mar-
kers (homozygosity mapping), we found a large segment
of homozygosity in chromosome 11q23 comprising
about 2,896 SNP shared by two affected sisters and non-
shared by the unaffected siblings. This region includes
the APOA5/A4/C3/A1 gene cluster, which in turn con-
tains APOA5 as a primary candidate gene. Direct sequen-
cing of the APOA5 gene revealed a homozygous nonsense
mutation (p.Gln97Ter; Q97X) in both affected sisters. In
this study, we show that homozygosity mapping is a useful
and efficient strategy to identify genetic loci responsible for
dyslipidemias in consanguineous families.
Subjects and methods
Subjects
Figure 1 shows the genealogy of the most relevant subset
of the consanguineous family under study (see Additional
file 1: Figure S1 for the complete pedigree). Saliva samples
were obtained for DNA analysis from 19 family members
using the Oragene DNA OG-250 kits (www.dnagenotek.
com). We conducted a brief medical interview with all
family members, requesting their medical history, past sur-
geries and diseases and medical treatments. We further
evaluated lifestyle variables and anthropometry. Writteninformed consent was obtained from the proband and
her relatives. Written informed consent was obtained
from the patient for publication of this Case report and
any accompanying images. A copy of the written consent
is available for review by the Editor of this journal. The
study protocol was approved by the Ethics Committee of
the School of Medicine of the Pontificia Universidad
Católica de Chile (protocol number 09–112).
The proband (subject 11) is a 46-year-old woman who,
since age 22, has presented severe HTG, with maximum
plasma TG levels of 112 mmol/L. After suffering acute
pancreatitis during her first pregnancy, she required
weekly plasmapheresis during subsequent pregnancies in
order to maintain plasma TG levels below 11 mmol/L.
The proband has no co-morbidities associated with
HTG and shows normal body weight. Currently, her
condition is kept under control with diet and associated
therapy (fibrates and nicotinic acid). Her sister (subject
12), age 50, has presented severe HTG since the age of
30. She has reached a maximum TG level of 116 mmol/L
and has suffered several episodes of acute pancreatitis.
She has been diagnosed as pre-diabetic, is overweight,
and has required emergency plasmapheresis on several
occasions. Currently, she is under treatment with fibrates
and omega-3 fatty acids.
The brother of the proband (subject 13) has an inter-
mediate phenotype, presenting TG levels >5.6 mmol/L,
but not higher than 22 mmol/L. He has not presented
episodes of acute pancreatitis. He is diabetic and obese.
Although he has previously required fibrates, his condi-
tion is currently kept under good control with atorvasta-
tin only. Another younger sister of the proband (subject
14) has never presented severe HTG. The father (subject
8) was diagnosed with diabetes and died at age 69 of
coronary heart disease. Subject 9, a paternal uncle of the
affected sisters, is diabetic, overweight and presents an
intermediate phenotype with a maximum known level of
TG of 9 mmol/L. The mother of the affected sisters
(subject 7) is diabetic, obese, and also shows an inter-
mediate phenotype with a maximum TG of 12 mmol/L,
and without previous episodes of acute pancreatitis.
In 2006, levels of apolipoprotein C-II and C-III, lipid
profile and blood glucose levels were measured in most
of the members of the family (see lower part of Figure 1).
It is worth mentioning that the mother and the sister of
the proband showed elevated levels of Apo C-II and
Apo C-III.
Genome scan
Genomic DNA from saliva was checked for integrity,
treated with RNAse and fluorometrically quantified
(Qubit platform, Invitrogen). A genome-wide scan for
linkage was performed using the Human Cyto SNP-12
panel (http://www.illumina.com), which determines
Subject 7 9 11 12 13 14
Age (years) 77 79 46 50 51 45
BMI (kg/m2) 30 30 22.9 27.5 30.8 22.9
Diabetes Yes Yes No No Yes No
Prediabetes - - No Yes - No
TG max  (mmol/L) 12 9 112 116 ND 1.8
TG (mmol/L)* 9 ND 1.6 38 5 2
Apo-CIII (mg/dL)* 53.1 ND 12.5 63.4 9.5 15.7
Apo-CII (mg/dL)* 12.8 ND 5.9 19.5 4 5.6
Figure 1 Clinical characteristics and haplotypes of the APOA5 gene and its flanking region in a consanguineous Chilean family with
hypertriglyceridemia. Arrow: proband (subject 11); Solid symbols: patients with triglycerides (TG) >56 mmol/L; Grey-filled symbols: patients with
5.6 < TG < 22 mmol/L; Double line: consanguineous marriage. Rs numbers represents SNPs flanking the APOA5 gene. In table: Grey-filled
columns: patients with severe chylomicronemia (TG >56 mmol/L), homozygous for 97X mutation; * Tests taken on 2006; TG: Triglycerides; BMI:
Body Mass Index; ND: Not Determined; Plasma Apo C-III normal range: 1.2 – 17.2 mg/dL. * Subject`s 8 haplotype was inferred from relative’s
haplotypes.
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9.7 kb (see panel features in Additional file 1: Table S2).
Genotyping was carried out at the Spanish National
Genotyping Centre (CeGen; http://www.cegen.org).
Using our own controls, the genotyping success rate,
reproducibility (two sets of duplicate samples) and
Mendelian consistency (case-parent trios from the family)
were above 99%.
Statistical analysis
Genotypes were analyzed with the PLINK software. R
routines were created at the School of Mathematics of
the Pontificia Universidad Católica of Chile to display
areas of homozygosity (routines are available under re-
quest). Using such R routines, genome regions showing
excess homozygosity (initially defined in an arbitrary
way as >100 consecutive SNPs) shared by the two
affected sisters, but not by healthy siblings, were identi-
fied as candidate regions for containing a disease locus
responsible for the severe HTG.
We also carried out a formal LOD score calculation to
assess linkage in the regions that showed excess homo-
zigosity [23]. Genetic markers flanking the APOA5/A4/
C3/A1 cluster were assessed first since this locus showed
the largest number of consecutive homozygous SNPs in
the initial scan. To reduce the computational burden of
multipoint linkage analysis and to increase marker infor-
mation, the complete haplotype, defined by six SNPs
flanking the APOA5/A4/C3/A1 cluster (rs3741301,
rs10488698 rs6640, rs1263173, rs2849176 and
rs11216162), was used for LOD score calculations under
a recessive model of complete penetrance. We used a
modified version of the MLINK 4.03 program compiled
for analysis of pedigrees with multiple consanguinity-
loops [25]. A LOD score > 3 is highly suggestive of link-
age, while LOD scores < −2 suggest linkage exclusion
[25]. (See Additional file 1: Methods for specification of
parameters used in the linkage analysis).
Genetic analysis of APOA5 gene
Primers were designed for sequencing APOA5 exons and
intron-exon boundaries. Genomic DNA was amplified
through PCR (see detailed information in Additional file 1:
Methods). Once the causative mutation was detected
(Q97X), a PCR-RFLP assay was developed to identify such
mutation in other family members and to verify its absence
in 50 anonymous DNA samples. Additionally, S19W
(rs3135506) and -1131T>C (rs662799) polymorphisms of
the APOA5 gene were genotyped in all family members [9]
(detailed information in Additional file 1: Methods).
Results
Fifteen regions were identified as a) having excess of
homozygosity (arbitrarily defined as > 100 consecutivehomozygous SNP) shared by the two affected cases (sub-
jects 11 and 12), and simultaneously, b) showing a sub-
stantial heterozygosity in the non-affected sister (subject
14; with heterozygosity found in at least 20% of the
SNP). The size of these regions ranged from 13,310 kb
to 195,339 kb, (from 100 to 3,000 consecutive homozy-
gous SNP) (Additional file 1: Table S3). The APOA5/
A4/C3/A1 cluster is located in the largest homozygous
region shared by the two affected cases (2,860 consecu-
tive homozygous SNP) (Figure 2). Given that the
APOA5/A4/C3/A1 cluster has been described in the
literature as responsible for increased plasma TG
levels, this locus was considered as the primary candi-
date region responsible for severe HTG in the family
[27]. The possible location of a causal mutation in this
locus was furthermore supported by classical linkage
analysis under a recessive model of complete pene-
trance, with a calculated LOD score of 2.02.
Considering the clinical characteristics displayed by the
affected cases in the family under study (subjects 11 and
12; HLP type V), the most probable candidate gene within
the APOA5/A4/C3/A1 cluster for carrying a mutation
was the APOA5 gene [9,28]. Therefore, we proceeded to
sequence analysis this gene, which led to the detection of
a known single nucleotide nonsense substitution in exon
4, which changes a glutamine at position 97 into a prema-
ture stop codon (mutation NM_001166598.1:c.289C>T;
NP_001160070.1:p.Gln97Ter, named from now on Q97X)
(Additional file 1: Figure S3). Sequencing and PCR-RFLP
analysis showed that the proband and her affected sister
(subjects 11 and 12) are homozygous for this nonsense
mutation, while subjects 7, 9 and 16 are heterozygous for
the mutation. Additionally, subjects 13 and 14 were found
to be non-carriers (Figure 1; Additional file 1: Figure S1
and S3). Descendants of subjects 11 and 12 are obligatory
heterozygous carriers, although their DNA was not avail-
able for this study (Additional file 1: Figure S1). The mu-
tation Q97X was not found in other family members
among those with available DNA, being absent in 50
anonymous DNA samples from Chilean unrelated
blood donors.
We also evaluated the common genetic variants
APOA5 S19W and -1131T>C in this family as they have
been significantly related to multifactorial hypertriglycer-
idemia [28,29] (Figure 1 and Additional file 1: Figure
S3). Heterozygous carriers of the Q97X mutation
showed homozygous wild-type genotypes for APOA5
S19W and -1131T>C, except for subject 8 (inferred
genotype) and subject 9, who showed a heterozygous
genotype in the APOA5 S19W polymorphism.
Discussion
We have conducted a genome-wide search for shared
homozygosity in affected sibs in order to identify the
Figure 2 Homozygous and heterozygous regions determined through homozygosity mapping in a consanguineous Chilean family
with hypertriglyceridemia. Chr: chromosome; Numbers, 11: proband; 12: affected sister; 13 and 14: nonaffected siblings; 7: mother; Solid
regions: heterozygosity in markers; Open regions: homozygosity in markers.
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guineous Chilean family. There are three strategies com-
monly used to search for rare causative mutations in
severe monogenic diseases in families: a) genome or
exome sequencing, b) linkage analysis followed by se-
quencing of candidate genes within the genomic area
significant for linkage, and c) resequencing all candidate
genes related to the disease. Exome/genome sequencing
(a) is becoming with no doubt a key tool to find disease-
causing mutations [30]. The use of exome sequencing
approach would have been clearly successful in the iden-
tification of the genetic cause of HTG in our family.
However, in a more general context, there are still some
challenges associated with the exome sequencing strat-
egy. It has been estimated that each individual exome
harbors around 20,000 sequence variants in comparison
with the human reference genome, including 5,000 var-
iants affecting amino acid sequence. After filtering with
common genetic variation found in databases, still many
variants are left as candidate causal, even if we consider
recessive defects [31,32]. Linkage analysis (b) is a clas-
sical genetic strategy to search for causal loci responsible
of genetic diseases which is based on the use of a map of
genetic markers (microsatellite markers or SNP) across
the genome. A special case of linkage analysis is the so-
called homozygosity mapping strategy, which has been
extensively used in the study of genetic causesunderlying diseases with recessive effect in consanguin-
eous families. In these types of studies, the objective is
to identify homozygous markers shared by the affected
cases that pinpoint genomic regions that may contain
the responsible gene and mutation [23]. It is important
to mention that the combination of genome/exome se-
quencing and homozygosity mapping is an appealing ap-
proach that has been successfully applied in the
identification of mendelian diseases [33]. Direct sequen-
cing of candidate genes (c) is conceptually the most
straightforward approach to find causal mutations. How-
ever, there are some important considerations that
should be taken into account regarding the laboratory
effort required for resequencing studies. Sequencing the
five most plausible candidate genes for severe HTG
(LPL, APOC2, APOA5, LMF1 and GPIHBP1) would in-
clude the analysis of ten exons of the LPL gene (main
candidate gene), four exons of the APOA5 gene, thirteen
exons of the LMF1 gene, four exons of the GPIHBP1
gene and five exons of the APOC2 gene (a total of 36
exons). If no mutation is found initially in these genes,
next logical steps would be the search for novel muta-
tions in genes with common variants that have been
associated with multifactorial HTG through genome-
wide association studies such as for example GCKR (19
exons), and possibly testing genes with loss-of-function
mutations causing hypotriglyceridemia (for example, 6
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among others). Therefore, resequencing genes with trad-
itional techniques may represent an important invest-
ment in terms of time, especially if the causative
mutation is not found in the initial steps. In contrast,
the timeframe we have employed in this homozygosity
mapping study in submitting DNA to genome-wide ana-
lysis, locating the causative gene and discovering the
mutation was of approximately 6 months. This was
possible because the homozygosity mapping directly
led us to the chromosomal region in which the causal
mutation is located. As stated before, another advantage
of the homozygosity mapping strategy is that limits the
search for candidate mutations provided by exome se-
quencing in consanguineous families [34], and provides
the possibility to identify new genes not previously
described as responsible for extreme phenotypes. On the
contrary, the main limitation of homozygosity mapping
is that it requires consanguineous families. It is also im-
portant to notice that sometimes (especially in small
families), this method pinpoints a very large chromo-
somal region, in which hundreds of genes could be re-
sponsible of the causal mutation. It is also important to
mention that diseases caused by compound heterozygous
are not detectable using this strategy. In our study,
homozygosity mapping correctly pinpointed the region
carrying the gene responsible for the disease [9,28] in
11q23 that contains APOA5/A4/C3/A1 gene cluster.
After Sanger sequencing, the Q97X mutation of the
APOA5 gene was identified in a homozygous state in the
two affected sisters and in a heterozygous state in other
family members. Although statistical power for finding
significant LOD scores is always increased with larger
number of affected and unaffected relatives, it is note-
worthy to mention that the discovery of mutations is
possible using only a single family [25]. Given the argu-
ments presented above, we believe that homozygosity
mapping is a valid and fast approach to locate causal re-
cessive mutations in consanguineous families. This
power of this strategy is enhanced when used in combin-
ation with resequencing of candidate genes or exome se-
quencing techniques.
The APOA5 gene is located on chromosome 11q23,
within the APOA1/C3/A4/A5 gene cluster, a well-
studied region that had previously been associated with
variations in plasma TG [27]. Apo A-V protein was dis-
covered in 2001 by two research teams simultaneously
[35,36]. This apolipoprotein is synthesized in the liver
and is associated with very low density lipoprotein
(VLDL), chylomicrons (QM) and high-density lipoprotein
(HDL). Its concentration in plasma is very low (0.1-0.4
μg/ml), which is approximately 300-fold lower than Apo
C-III and roughly 2000-fold lower than Apo A-I [9,28,37].
It has been proposed that Apo A-V influences plasma TGlevels primarily by increasing the catabolism of TG-rich
lipoproteins through stimulation of LPL [38-41] or alter-
natively by inhibiting the rate of production of VLDL
[42]. It was demonstrated that adenoviral overexpression
of Apo A-V in mice is related to a 70% reduction in TG
levels compared to wild-type mice, while Apoa5 knock-
out mice showed a four-fold plasma levels relative to con-
trols [43,44]. In humans, an inverse association between
plasma Apo A-V and TG levels has been reported in
cases of homozygous APOA5 nonsense mutations [9],
whereas other reports indicate higher ApoA-V plasma
concentrations in HTG patients [45]. Interestingly, it has
been shown that intravenous injection of ApoA-V into
apoa5 knock-out mice induces a 60% decrease in plasma
TG after four hours [46].
An excess of rare APOA5 variants have been found in
HTG patients, providing evidence for the importance of
APOA5 in this disorder [47]. Mutations in the APOA5
gene have been described in cases of severe chylomicro-
nemia, such as the Q148X mutation, Q139X mutation,
IVS3+3G>C and three heterozygous missense variants
[48-51]. The phenotypic expression of these mutations is
highly variable, especially in heterozygous subjects, who
usually require additional adverse environmental triggers
(e.g. obesity, diabetes) or the presence of other suscepti-
bility genetic variants. The Q97X mutation found in this
study was described for the first time by Oliva et al. [52]
and subsequently by Charriere et al. [53]. After the re-
moval of the endoplasmic reticulum signal peptide of 23
amino acids, this mutation would cause truncation at
residue 74 of the mature protein (343 amino acids) [54],
creating a predicted 10 kDa peptide instead of the 39
kDa complete protein. This peptide, if synthesized (see
discussion on NMD below), would lack the essential do-
main for lipid binding and LPL activation (residues 192
to 238) and therefore is expected to be non-functional
[41,55] (Additional file 1: Figure S4 shows our own pre-
diction model of the Apo A-V protein structure). In
these previous reports on homozygous patients carrying
the Q97X mutation, neither wild-type nor truncated
Apo A-V were detected in plasma, thus suggesting a
complete Apo A-V deficiency [52,53].
There is a remarkable variability shown by affected
HTG cases that are carriers of the Q97X mutation in
different studies, especially in terms of drug require-
ments, responsiveness to treatment, age of onset, TG
plasma levels and other clinical manifestations [52,53]
(See Additional file 1: Table S4). For example, heterozy-
gous Q97X carriers reported by Oliva et al. showed phe-
notypes ranging from severe hyperchylomicronemia to
normotriglyceridemia [52]. It is possible that partial Apo
A-V deficiency by itself is not sufficient to trigger severe
HTG unless adverse environmental stimuli overload the
lipolytic system [52,53]. Similar observations have been
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other APOA5 mutations (Q139X, Q148X) [9,48,49,56].
In our study, two heterozygous carriers of the mutation
(subjects 7 and 9) are both diabetic and overweight,
showing an intermediate phenotype of HTG. They
developed severe HTG although never reached TG
values as high as the two homozygous 97X sisters, with
no history of acute pancreatitis. On the other hand, the
two homozygous affected sisters showed triglycerides
levels much higher than in the cases previously
described (112 mmol/L compared to 11 mmol/L in the
case reported by Oliva and 40 mmol/L in the case
reported by Charriere) [52,53]. It is possible that our
patients carry other alleles that contribute to this more
severe phenotype, such as common or rare gene variants
described in the APOE, LPL or APOB genes [16,21,22].
The fact that heterozygous carriers of this autosomic
recessive disease also show some pathologic manifesta-
tions indicates either haploinsufficiency or a dominant
negative effect of the truncated protein. In the first case,
LPL may play its role properly in adequate conditions
maintaining plasma TG levels within a normal range.
However, if the system is subjected to an overload due
to adverse environmental factors, the enzyme is no
longer able to maintain normal TG metabolism, and
HTG appears. In the second case, it can be postulated
that the truncated peptide has a negative effect by itself.
In this context, NMD (Nonsense Mediated mRNA
Decay) is a cellular mechanism that eliminates mRNA
that carries a premature stop codon in order to prevent
the synthesis of truncated proteins. It has been proposed
that NMD is not effective on premature stop codons
located in the last exon of the gene or less than 50
nucleotides upstream of the last splice junction [57].
Thus, it is possible that the NMD mechanism does not
occur in the Q97X premature stop codon, and the trun-
cated protein is synthesized and itself interferes with the
mature Apo A-V. Although previous reports of Q97X
mutations did not find the truncated peptide plasma
[52,53], one report indicates that the mature protein did
not properly bind to TG-rich lipoproteins in Q97X het-
erozygotes [53], suggesting that truncated peptide may
be synthesized but not secreted to the plasma.
APOA5 is a relatively polymorphic gene showing com-
mon variants in the promoter region (−1131T>C) and in
the signal peptide (S19W) that have been previously
associated with elevated plasma TG levels [28,29,58].
Recently, APOA5 -1131T>C polymorphism has been
associated with higher plasma TG levels in a large epide-
miologic study (16% increase for every C allele inherited)
[59]. The presence of susceptibility alleles for HTG in
APOA5 -1131T>C and S19W might be important in het-
erozygous carriers of Q97X when the mutation is located
in a different haplotype than the susceptibility commonvariants APOA5 -1131C and 19W. In the French pedi-
gree described by Charriere et al., most of the Q97X het-
erozygotes carried another susceptibility haplotype on
the second chromosome [52]. Similar results were
observed in the report by Marcais et al. [49]. In our fam-
ily, only one of the three Q97X heterozygous subjects
showed the 19W susceptibility allelic variant (subject 9),
while the other heterozygous subjects showed the wild-
type genotype in the -1131T>C variant (Figure 1). It is re-
markable that even though subject 9 also carries the
19W susceptibility variant, he has not developed a more
severe disease compared with heterozygous subject 7,
who shows wild type S19 homozygous genotype. Never-
theless, we consider that it is not possible to assess the
influence of S19W common variants in Q97X heterozy-
gous subjects, given the limited number of subjects in
this family.
Regarding Apo C-III levels, both the mother (subject
7) and one of the affected sisters of the proband (subject
12) in our study showed elevated levels of Apo C-III. It
is remarkable that both were the only ones displaying se-
vere HTG (>5.6 mmol/L) at the time the test was per-
formed in 2006, when even the proband (who was under
treatment) showed normal TG levels and also normal
levels of this apolipoprotein (Figure 1). In previous
reports on Q97X and other APOA5 mutations that lead
to Apo A-V deficiency, higher levels of Apo C-III in the
mutation carriers have also been described [48,49,52,53].
In fact, a 2.7-fold increase of Apo C-III was observed in
Apo A-V deficient plasma compared to control plasma
[48]. Furthermore, the S19W and −1131 T>C variants in
the APOA5 gene have been associated with higher levels
of Apo C-III [60]. On the other hand, it has also been
described that hypertriglyceridemic patients display
higher levels of this apolipoprotein compared to controls
[61]. All these observations suggest a complex relation
between Apo A-V and Apo C-III. Therefore, it is possible
that the impaired TG hydrolysis in Apo A-V deficient
plasma is a consequence of the lack of an LPL activator
(Apo A-V), as well as the presence of an inhibitor (Apo
C-III) [62]. The proband in our study, who is homozy-
gous for the Q97X mutation and should have a deficiency
of Apo A-V in plasma, did not show elevated levels of
Apo C-III. Therefore, the observation of normal Apo C-
III in the proband may suggest that, in our patients,
plasma Apo C-III levels are mainly determined by HTG
itself and not by the Apo A-V deficiency.
Conclusions
We have identified a mutation in the APOA5 gene
(p.Gln97Ter; Q97X) responsible for severe HTG in a
consanguineous Chilean family using a genome-wide
approach based on the homozygosity mapping strategy.
The causative locus was initially located in the APOA5/
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the APOA5 gene as a nonsense substitution Q97X. In
our family, homozygotes for Q97X showed plasma TG
levels > 112 mmol/L, while heterozygous family members
showed a less severe phenotype. In general, the pheno-
typic expression of this mutation is highly variable, espe-
cially in heterozygous, where adverse environmental
factors and other pathologic conditions may play a fun-
damental role in the manifestation of the disease.
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APOA5. Supplemental figures: Figure S1. Pedigree chart of the complete
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APOA5 gene. Figure S4. Model of Apo A-V protein structure and critical
domains.
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